Latest News and Press Releases

- Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration - - RT-116 was well tolerated...

Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Type 1 Diabetes: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.This report covers the 68...

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing...

YMCA offers a free diabetes prevention program. Participants can learn more at our wellness day on January 29 at Castle Downs Family YMCA.

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

WARSAW, Poland, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Medisensonic S.A., a Polish MedTech joint-stock company with an estimated market value of more than €15 million, is one of the very promising...

Amwell® adds Vida to its clinical programs portfolio expanding access to obesity and diabetes care.

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented...

Beta Bionics, Inc., a leader in the development of advanced diabetes management solutions, announced that it has filed a Form S-1 with the SEC.

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...